ZBH

In the past six months (April 2026 - October 2026), Zimmer Biomet Holdings, Inc. experienced several notable stock events. In June 2026, the company entered into an agreement to acquire the iovera pain therapy business from Pacira BioSciences Inc. for $140 million. A $1.5 billion share repurchase program was authorized in February 2026. On August 5, 2026, the company announced its second-quarter 2026 financial results, reporting revenue of $2.18 billion (a 4.8% year-on-year growth) and adjusted EPS of $2.07, leading management to slightly raise its full-year adjusted EPS guidance. A quarterly dividend for the third quarter of 2026 was announced on September 23, 2026, with an upcoming payout on October 30, 2026. On September 8, 2026, Zimmer Biomet announced Americas Leadership Promotions to accelerate commercial transformation. The stock experienced fluctuations, gaining 0.83% during the 61 trading days leading up to October 2, 2026, reaching a high of $102.86 on September 1, 2026, and a low of $86.33 on July 9, 2026. The stock also saw a largest daily move of -15.1% on November 5, 2025, and a 1-year change of -11% from October 1, 2025, to October 1, 2026, with its price falling by 5.88 percent over the last 12 months.